Key Highlights
- Morgan Stanley maintains Overweight rating on Eli Lilly (LLY) stock with $1,313 price objective
- Mounjaro prescriptions increased to ~724,500 weekly, rising from ~705,300 previously
- Zepbound prescriptions surged to ~598,100, climbing from ~500,900 in the prior week
- Company’s GLP-1 portfolio captures approximately 60% of weekly new prescription market share
- Fourth quarter EPS reached $7.54, surpassing forecasts, while revenue jumped 42.6% annually
Eli Lilly’s leading weight-loss and diabetes medications, Mounjaro and Zepbound, demonstrated prescription volume increases during the week concluded February 27, 2026, based on IQVIA data referenced by Morgan Stanley analysts.
Mounjaro recorded approximately 724,500 total prescriptions during the reporting period, representing an increase from the previous week’s tally of around 705,300. New Mounjaro prescriptions totaled roughly 361,600, advancing from 352,700 in the preceding week.
Zepbound experienced an even more pronounced surge. Total prescriptions climbed to about 598,100, substantially higher than the prior week’s 500,900. New prescriptions advanced to 328,300 from 298,600.
Morgan Stanley maintained its Overweight stance on LLY shares and preserved its $1,313 price objective. The investment firm anticipates approximately 7% upside potential relative to its 2026 projections for both medications combined.
Combined GLP-1 prescription volumes for Lilly and Novo Nordisk expanded roughly 30% on a year-over-year basis, demonstrating sustained robust demand throughout the therapeutic category.
Lilly’s complete GLP-1 product portfolio — Mounjaro, Zepbound, and Trulicity — captured approximately 60% of weekly new prescription market share, edging higher from the prior week’s 59%.
Financial Performance and Results
LLY delivered Q4 EPS of $7.54, exceeding Wall Street consensus expectations of $7.48 by $0.06. Revenue totaled $19.29 billion, significantly surpassing the $17.85 billion estimate. This represented a 42.6% increase compared to the corresponding quarter in the previous year.
The pharmaceutical giant established its FY2026 guidance range at $33.50–$35.00 EPS. Net profit margin for the quarter reached 31.66%, while return on equity measured 102.94%.
Lilly increased its quarterly dividend payment to $1.73, advancing from $1.50. The annualized distribution now totals $6.92, translating to a yield of approximately 0.7%.
Shares began trading Friday at $982.85. The 52-week trading range extends from $623.78 to $1,133.95. The 50-day moving average currently stands at $1,047.37, while the 200-day moving average registers at $937.23.
Wall Street Ratings and Institutional Holdings
Institutional investors currently hold 82.53% of LLY shares. Several investment firms expanded their positions throughout Q3 2026, including KCM Investment Advisors, which boosted its holdings by 14%, and M1 Capital Management, which increased its stake by 10.8%.
Integrity Advisory Solutions established a new position valued at approximately $1.07 million during the reporting period.
The Wall Street consensus rating stands at “Moderate Buy” with an average price objective of $1,229.59. Wells Fargo increased its target to $1,280 while maintaining an Overweight rating. Jefferies elevated its target to $1,300, assigning the stock a Buy rating. Royal Bank of Canada initiated coverage with an Outperform rating and established a $1,250 price target.
Seven Wall Street analysts revised their earnings projections upward following the fourth quarter earnings announcement.
Lilly additionally introduced its “Employer Connect” initiative, structured to assist employers in providing coverage for obesity medications, including Zepbound, featuring a $449 single-patient KwikPen pricing option.
Orforglipron, Lilly’s investigational oral GLP-1 compound, outperformed oral semaglutide in a Type 2 diabetes clinical trial across both primary and secondary outcome measures.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
